#3-02E. Optimizing RA Management: Comparative Efficacy and Safety of JAK Inhibitors (Pharmaceuticals, 2025)

With the rapidly expanding arsenal of Janus kinase inhibitors (JAKinibs) for rheumatoid arthritis, clinicians face the complex challenge of selecting the optimal agent for individual patients based on varying risk profiles. This episode examines a comprehensive network meta-analysis incorporating 39 randomized controlled trials with nearly 17,000 participants to compare the relative performance of six JAKinibs, including tofacitinib, baricitinib, and upadacitinib. The study provides a granular hierarchy of treatment options, identifying high-dose decernotinib as the leader in ACR50 response rates, whereas tofacitinib demonstrated the most favorable safety profile with the lowest incidence of adverse drug reactions. Crucially, while upadacitinib proved highly effective, it was associated with a notably higher risk of adverse events. When interpreting these findings, physicians must exercise caution regarding agents like decernotinib, as their promising data rest on a limited number of trials compared to established drugs, and the analysis is constrained by the relatively short duration of included studies, leaving long-term safety questions open. For the practicing rheumatologist, this analysis offers a vital evidence-based framework to navigate the clinical trade-offs between potency and tolerability, facilitating more personalized and risk-stratified therapeutic decisions.

Citation: Almoallim, H.M., et al. Comparative Efficacy and Safety of JAK Inhibitors in the Management of Rheumatoid Arthritis: A Network Meta-Analysis. Pharmaceuticals. 2025.

DOI: 10.3390/ph18020178

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.